6 Results for "

RNA interference (RNAi)

" in MedChemExpress (MCE) Product Catalog:
Products (6)

6 Results for "RNA interference (RNAi)" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-112760
CAS No.: 247925-28-6
Purity:  ≥98.0%
Synonyms: DSPE-mPEG2000 sodium; 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] sodium
18:0 mPEG2000 PE (DSPE-mPEG2000) sodium is a conjugate of phospholipid and polyethylene glycol, and it can serve as an important PEG lipid component in lipid nanoparticles (LNPs). 18:0 mPEG2000 PE sodium can be used in the research of gene transfection, drug carriers and drug delivery .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-132606A
CAS No.: 2247026-22-6
Synonyms: DCR-PHXC sodium
Nedosiran (DCR-PHXC) sodium is an RNA interference (RNAi) targeting lactate dehydrogenase (LDH). Nedosiran sodium represents an impactful potential therapeutic for primary hyperoxaluria (PH) with end-stage renal disease (ESRD). Nedosiran sodium is a GalNAc-dsRNA conjugate .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-132613
CAS No.: 1834612-06-4
Purity:  99.21%
Lumasiran sodium, an investigational RNA interference (RNAi) therapeutic agent, reduces hepatic oxalate production by targeting glycolate oxidase. Lumasiran sodium reduces urinary oxalate excretion, the cause of progressive kidney failure in primary hyperoxaluria type 1 (PH1) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-132606
CAS No.: 2266591-83-5
Synonyms: DCR-PHXC
Nedosiran (DCR-PHXC) is an RNA interference (RNAi) targeting lactate dehydrogenase (LDH). Nedosiran represents an impactful potential therapeutic for primary hyperoxaluria (PH) with end-stage renal disease (ESRD). Nedosiran is a GalNAc-dsRNA conjugate .
loading...
    loading...
Cat. No.: HY-145720
CAS No.: 1639264-46-2
Synonyms: ALN-CC5
Cemdisiran (ALN-CC5) is an N-acetylgalactosamine-conjugated RNAi agent and also a complement component C5 inhibitor. Cemdisiran targets C5 mRNA, cleaves C5 mRNA via the endogenous RNA interference pathway, and inhibits the production of C5 protein in the liver. Cemdisiran exerts a dose-dependent inhibitory effect on total C5 concentrations in cynomolgus monkeys. When used in combination with Pozelimab (HY-P99786) in cynomolgus monkeys, Cemdisiran achieves a more sustained and complete inhibitory effect on complement activity. Cemdisiran can be used in the research of paroxysmal nocturnal hemoglobinuria and other complement-mediated diseases .
loading...
    loading...
Cat. No.: HY-145720A
Purity:  96.02%
Synonyms: ALN-CC5 sodium
Cemdisiran sodium (ALN-CC5 sodium) is an N-acetylgalactosamine-conjugated RNAi agent and also a complement component C5 inhibitor. Cemdisiran sodium targets C5 mRNA, cleaves C5 mRNA via the endogenous RNA interference pathway, and inhibits the production of C5 protein in the liver. Cemdisiran sodium exerts a dose-dependent inhibitory effect on total C5 concentrations in cynomolgus monkeys. When used in combination with Pozelimab (HY-P99786) in cynomolgus monkeys, Cemdisiran sodium achieves a more sustained and complete inhibitory effect on complement activity. Cemdisiran sodium can be used in the research of paroxysmal nocturnal hemoglobinuria and other complement-mediated diseases .
loading...
    loading...